MediciNova, Inc. — Form 10-Q Summary
Business context and reporting period
MediciNova is a biopharmaceutical company developing therapies for serious diseases with unmet medical needs. Its principal programs include MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine), and MN-029 (denibulin). The filing covers the unaudited quarter ended March 31, 2022, and was filed May 12, 2022. The company reported 49,043,246 shares outstanding at March 31, 2022 and 49,046,246 shares outstanding as of May 12, 2022.
Financial condition and key metrics
| Metric | Three months ended March 31, 2022 | Three months ended March 31, 2021 |
|---|---|---|
| Revenue | $0.0 million | $4.0 million |
| Research, development and patents expense | $2.1 million | $2.1 million |
| General and administrative expense | $1.3 million | $2.1 million |
| Total operating expenses | $3.4 million | $4.2 million |
| Operating loss | $3.4 million | $0.2 million |
| Net loss | $3.4 million | $0.2 million |
| Basic and diluted net loss per share | $0.07 | $0.00 |
| Net cash used in operating activities | $3.7 million | $3.9 million |
| Cash and cash equivalents at period end | $67.7 million | $76.3 million |
At March 31, 2022, total assets were $84.2 million, total liabilities were $3.8 million, and stockholders’ equity was $80.4 million. Working capital was $65.9 million. The company had no debt reported as such; liabilities primarily consisted of accounts payable, accrued liabilities, lease liabilities, deferred taxes, and other non-current liabilities. Operating lease liabilities totaled $0.8 million.
The company’s accumulated deficit was $396.4 million at March 31, 2022. Research and development expenses included approximately $1.6 million of external development spending on MN-166. Stock-based compensation expense declined to $0.1 million from $1.1 million in the prior-year quarter.
Material changes versus the prior comparable period
- Revenue declined $4.0 million to zero because the prior-year quarter included two development milestone payments under the Genzyme Agreement.
- Operating loss increased to $3.4 million from $0.2 million, primarily because of the absence of the prior-year milestone revenue.
- Research and development expense was broadly unchanged; higher MN-166-related costs were offset by lower performance-based stock option expense.
- General and administrative expense decreased $0.8 million, mainly due to lower performance-based stock option expense.
- Operating cash use improved by approximately $0.1 million, but the company received no financing proceeds in the 2022 quarter versus $20.1 million of net financing proceeds in the 2021 quarter from a private placement and related equity transactions.
- Cash declined by $3.7 million during the quarter, from $71.4 million at December 31, 2021 to $67.7 million at March 31, 2022.
Guidance, outlook, commentary, risks and unusual items
Management expects substantial net losses to continue for the next several years as product development programs advance. Research, development and patent costs are expected to increase through the remainder of 2022 as development programs progress. Management stated that available working capital is believed sufficient to fund operations at least through the end of 2023, but cautioned that this may not be sufficient to conduct all planned research and development programs.
The company intends to advance MN-166 through investigator-sponsored, grant-funded, company-funded and potentially partnered trials, and to pursue MN-001 development through similar funding sources. Management is also seeking strategic alliances to support development and commercialization of its product candidates.
COVID-19 reduced patient visits at certain clinical trial sites, but the company reported improving visits, continued enrollment, and continued regulatory and site-initiation activities. Management did not expect a material negative impact on development plans, timelines or liquidity based on its assessment at the filing date. The company’s MN-166 application for prevention of COVID-19-related acute respiratory distress syndrome had been accepted by the FDA, and the proposed investigation was allowed to proceed.
- Clinical development, enrollment, safety, efficacy and regulatory approval remain significant uncertainties.
- The company depends on MN-166 and MN-001 and on third parties for clinical trials, manufacturing, marketing and distribution.
- Additional capital may be required, and the company may be unable to raise financing on acceptable terms or at all.
- Potential future milestone payments under license agreements totaled $10.0 million for MN-166 and MN-001 and $33.5 million for other products as of March 31, 2022; timing is uncertain and depends on development progress.
- The company and Kissei were working to terminate their collaboration agreement and cancel the remaining MN-221 study, with termination expected in 2022.
- No material legal proceedings were reported, and management stated that there were no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Whether the $67.7 million cash balance and stated funding runway through at least the end of 2023 remain adequate as development spending increases.
- Progress, enrollment, results and regulatory status of MN-166 and MN-001 programs, including the ARDS-related MN-166 study.
- Whether any new milestone, licensing, collaboration or partnership revenue can replace the $4.0 million of one-time Genzyme revenue recognized in 2021.
- The timing and potential cost of the disclosed $43.5 million of future development and commercialization milestones.
- The outcome and timing of termination of the Kissei agreement and cancellation of the remaining MN-221 study.
- Potential dilution from the $75.0 million ATM facility, stock options, and any future equity financing; no ATM shares were sold during the quarter.